Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors

被引：13

作者：

Rallidis, Loukianos S. ^{[1
]}

Liberopoulos, Evangelos N. ^{[2
]}

Vlachopoulos, Charalambos ^{[3
]}

Skoumas, Ioannis ^{[3
]}

Kolovou, Genovefa ^{[4
]}

Anastasiou, Georgia ^{[2
]}

Dima, Ioanna ^{[3
]}

Tousoulis, Dimitrios ^{[3
]}

Iliodromitis, Efstathios ^{[1
]}

机构：

[1] Natl & Kapodistrian Univ Athens, Attikon Univ Hosp, Med Sch, Dept Cardiol 2, Athens, Greece

[2] Univ Ioannina, Sch Hlth Sci, Fac Med, Dept Internal Med, Ioannina, Greece

[3] Natl & Kapodistrian Univ Athens, Hippokration Hosp, Med Sch, Dept Cardiol 1, Athens, Greece

[4] Metropolitan Hosp, Lipoprot Apheresis & Lipid Disorders Clin, Cardiometab Ctr, Athens, Greece

来源：

ATHEROSCLEROSIS | 2020年 / 309卷

关键词：

PCSK9; inhibitors; Very-high risk; Familial hypercholesterolaemia; Lipid-lowering therapy; LDL-Cholesterol target;

D O I：

10.1016/j.atherosclerosis.2020.07.018

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：67 / 69

页数：3

共 7 条

[1] Achimastos A, 2016, HORM-INT J ENDOCRINO, V15, P8, DOI [10.14310/horm.2002.1659, 10.1007/BF03401398]
[2] Bempedoic acid: a promising novel agent for LDL-C lowering
Agarwala, Anandita
Goldberg, Anne C.
[J]. FUTURE CARDIOLOGY, 2020, 16 (05) : 361 - 371
[3] Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session
Jia, Xiaoming
Al Rifai, Mahmoud
Liu, Jing
Agarwala, Anandita
Gulati, Martha
Virani, Salim S.
[J]. CURRENT ATHEROSCLEROSIS REPORTS, 2020, 22 (08)
[4] Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER
Karlson, Bjorn W.
Wiklund, Olov
Palmer, Michael K.
Nicholls, Stephen J.
Lundman, Pia
Barter, Philip J.
[J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2016, 2 (04) : 212 - 217
[5] Mach F, 2020, EUR HEART J, V41, P111, DOI [10.1093/eurheartj/ehz455, 10.15829/1560-4071-2020-3826]
[6] The changing landscape of lipid-lowering therapy after the new ESC/EAS guidelines for the management of dyslipidaemias: Launching the era of triple hypolipidaemic therapy in very high risk patients
Rallidis, Loukianos S.
[J]. ATHEROSCLEROSIS, 2020, 292 : 231 - 233
[7] PCSK9 inhibitors in clinical practice: Novel directions and new experiences
Rallidis, Loukianos S.
Skoumas, Ioannis
Liberopoulos, Evangelos N.
Vlachopoulos, Charalambos
Kiouri, Estela
Koutagiar, Iosif
Anastasiou, Georgia
Kosmas, Nikolaos
Elisaf, Moses S.
Tousoulis, Dimitrios
Iliodromitis, Efstathios
[J]. HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (04) : 241 - 245

← 1 →